# Catalent acquires ERYTECH's U.S. manufacturing facility for $44.5M

Catalent has acquired ERYTECH's U.S. cell therapy manufacturing facility for $44.5 million. The companies also entered a long-term supply agreement for eryaspase (GRASPA).

- Type: Acquisition
- Announced: 2022-04-25
- Where: United States (facility location not specified further), United States
- Value: $44.5M
- Status: announced
- Products: cell therapy manufacturing facility, eryaspase (GRASPA)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Catalent](https://endata.com/companies/36530.md) (acquirer)
- [ERYTECH Pharma](https://endata.com/companies/62484.md) (target)

## Sources

- [stocktitan.net](https://www.stocktitan.net/news/ERPY/erytech-sells-u-s-manufacturing-facility-and-enters-long-term-supply-69rkrrp1i6ee.html), 2022-04-25: "Catalent acquired ERYTECH’s U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 million."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.